iSTAR Medical’s MINIject device showed significant reduction in IOP and medication burden in a first-in-human trial, the company announced in a press release.
The prospective, open, international, multicenter STARI-I trial included 25 patients with mild to moderate primary open-angle glaucoma who were implanted with the MINIject MIGS device.
After 1 year, there was an average IOP reduction of 32.6% to a mean of 15.6 mm Hg, with 75% of patients being able to discontinue topical medication use, the release said.
In addition, endothelial cell density results after implantation showed minimal
Uncategorized